Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Viatris ( (VTRS) ).
On May 1, 2026, Viatris said Chief Financial Officer Theodora “Doretta” Mistras had voluntarily resigned to pursue another opportunity, with her CFO role ending May 8 and her employment concluding May 22, after a transition period. The company stressed her departure was not due to any dispute over financial reporting or controls and that she will receive only a pro rata 2026 bonus, without severance or accelerated equity.
On May 4, 2026, the board appointed long-time finance executive Paul Campbell, currently Chief Accounting Officer and Corporate Controller, as interim CFO effective May 8 while it searches for a permanent successor. Viatris highlighted Campbell’s two decades of experience at the company’s legacy Mylan business and his leadership of global accounting operations, signaling an emphasis on continuity and financial discipline during the transition as the group prepares to report first-quarter 2026 results on May 7.
The most recent analyst rating on (VTRS) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Viatris stock, see the VTRS Stock Forecast page.
Spark’s Take on VTRS Stock
According to Spark, TipRanks’ AI Analyst, VTRS is a Neutral.
The score is held back primarily by weak profitability (deep 2025 losses and negative P/E) despite solid and stable cash flow. Technicals are supportive due to a strong uptrend, but momentum is overbought, limiting the technical score. Guidance and corporate actions (cost-savings program and Biocon stake sale) are constructive, though near-term margin pressure, manufacturing disruption risk, and sizable one-time restructuring costs temper the outlook.
To see Spark’s full report on VTRS stock, click here.
More about Viatris
Viatris Inc. is a global healthcare company headquartered in the U.S., with major centers in Pittsburgh, Shanghai and Hyderabad. It operates across generics, established brands and innovative medicines, focusing on large-scale, durable therapies that address significant unmet medical needs worldwide and ensuring resilient supplies of essential treatments.
Average Trading Volume: 10,537,704
Technical Sentiment Signal: Buy
Current Market Cap: $17.51B
See more insights into VTRS stock on TipRanks’ Stock Analysis page.